Sai-Hong Ignatius Ou

Title(s)Health Sciences Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckl). 2023; 14:101-109. Nagasaka M, Ou SI. PMID: 38111829; PMCID: PMC10725831.
      View in: PubMed   Mentions:
    2. Response to "NGS, the New Global Standard?" J Thorac Oncol. 2023 Oct; 18(10):e116-e118. Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Thomas M, Stenzinger A. PMID: 37758351.
      View in: PubMed   Mentions:    Fields:    
    3. ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia. Lung Cancer (Auckl). 2023; 14:71-78. Lee ATM, Ou SI. PMID: 37440867; PMCID: PMC10335304.
      View in: PubMed   Mentions:
    4. The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckl). 2023; 14:63-69. Brazel D, Ou SI. PMID: 37383584; PMCID: PMC10296535.
      View in: PubMed   Mentions:
    5. From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckl). 2023; 14:57-62. Lee ATM, Ou SI. PMID: 37377783; PMCID: PMC10292622.
      View in: PubMed   Mentions:
    6. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 01; 139:22-27. Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. PMID: 31706099.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    7. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. ESMO Open. 2018; 3(5):e000364. Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT. PMID: 30018815; PMCID: PMC6045737.
      View in: PubMed   Mentions: 5  
    8. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 01; 12(1):145-151. Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F. PMID: 27697581; PMCID: PMC7249761.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    9. Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al. Ann Oncol. 2014 Oct; 25(10):2093. Ou SI, Pasi J. PMID: 25035278.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012 Sep; 83(3):407-21. Ou SH. PMID: 22257651.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    11. The effect of tumor size on non-size-based descriptors in staging of stage I non-small cell lung cancer. Chest. 2009 Jun; 135(6):1695-1696. Ou SI, Zell JA. PMID: 19497911.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Sai-Hong's Networks
    Concepts (37)
    Derived automatically from this person's publications.
    Co-Authors (3)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department